Macrophage Polarization States in the Tumor Microenvironment
Open accessThe DOI matches its Crossref record; 147 of the 148 references it cites were found in a registry or an index.
Abstract
The M1/M2 macrophage paradigm plays a key role in tumor progression. M1 macrophages are historically regarded as anti-tumor, while M2-polarized macrophages, commonly deemed tumor-associated macrophages (TAMs), are contributors to many pro-tumorigenic outcomes in cancer through angiogenic and lymphangiogenic regulation, immune suppression, hypoxia induction, tumor cell proliferation, and metastasis. The tumor microenvironment (TME) can influence macrophage recruitment and polarization, giving way to these pro-tumorigenic outcomes. Investigating TME-induced macrophage polarization is critical for further understanding of TAM-related pro-tumor outcomes and potential development of new therapeutic approaches. This review explores the current understanding of TME-induced macrophage polarization and the role of M2-polarized macrophages in promoting tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have shown that MSCs have the ability to polarize M1 pro-inflammatory macrophages towards an alternative M2 anti-inflammatory phenotype [21,22,23].”
From Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, CD4+ T cells impact cancer immunology (30), M1 macrophages suppress tumors, and M2 macrophages aid tumor growth (31).”
From A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer (2025) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 3×
“These CD8+ T and NK cells express high levels of cytokines such as IFN-γ, GM-CSF, and TNF-α as well as chemokines such as CCL4, CCL5, and CCL23 that assist in the further recruitment of immune cells and the signaling of anti-tumorigenic pathways [73,74].”
BackgroundMyeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 2×
“MDSCs express high levels of both iNOS and arginase-1, which both play a direct role in suppression of T-cell function [95].”
BackgroundOrigin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 1×
“Inflammation can be triggered by conditions such as infection or injury or can be systemic as seen in type 2 diabetes and cardiovascular disease [59].”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 3×
“Current literature supports the theory that most TAMs originate from either tissueresident embryonic macrophages or macrophages derived from circulating monocytes that originate in the bone marrow [87].”
BackgroundMANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 3×
“The significance of macrophage heterogeneity has been under review since the early 2000s and has been linked to many malignancies and autoimmune disorders in recent years [66].”
BackgroundProtective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“The resolution of inflammation is led by the deactivation of these inflammatory mediators, permitting either the apoptosis of pro-inflammatory M1 macrophages or the transition to an anti-inflammatory M2 macrophage [64].”
BackgroundMacrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 15×
“Macrophages are found in every human tissue in the body and exhibit anatomical and functional diversity [4].”
BackgroundInfluentialMurray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981 · cited 2×
“Some noncytokine, extrinsic pathways of macrophage polarization do exist, however, including hypoxia as well as the production of lactate within tumors, which drive M2 polarization [36].”
BackgroundFibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Cited by
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,229
“Nevertheless, the combination’s gene expression profiles vary from LPS and IFN-γ alone.(27) The PRRs, such as TLRs, recognize bacterial moieties.”
BackgroundRadiotherapy combined with immunotherapy: the dawn of cancer treatment
Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 670
M1/M2 macrophages and their overlaps – myth or reality?
Strizova, Z., Benesova, I., Bartolini, R., Novysedlak, R., Cecrdlova, E., Foley, L. K., & Striz, I. (2023) · Clinical Science · doi:10.1042/cs20220531 · Cited by 612
Macrophage polarization: an important role in inflammatory diseases
Luo, M., Zhao, F., Cheng, H., Su, M., & Wang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352946 · Cited by 468
“Macrophages exhibit diverse morphological and functional characteristics as they undergo polarization in response to speci fi c cytokines and growth factors present in the various tissues they inhabit (188).”
BackgroundImmunotherapy: Reshape the Tumor Immune Microenvironment
LV, B., Wang, Y., Ma, D., Cheng, W., Liu, J., Yong, T., Chen, H., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844142 · Cited by 482
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
“T cells, B cells, and antigen-presenting cells are collectively called specific immune cells, of which dendritic cells are a type of antigen presenting cell (APC) that integrates information from TME and transmits it to other immune cells [20].”
BackgroundImmune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments
Xu, J., Ding, L., Mei, J., Hu, Y., Kong, X., Dai, S., Bu, T., Xiao, Q., & Ding, K. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02325-5 · Cited by 389
“…TAMs in the tumor microenvironment are regulated by a variety of factors, including cytokines, chemical signals, and other immune cell interactions 2,3 At the same time, their functional plasticity allows them to regulate the immune response, angiogenesis, and metastasis, making them important in…”
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
Tumor-associated macrophages: an effective player of the tumor microenvironment
Basak, U., Sarkar, T., Mukherjee, S., Chakraborty, S., Dutta, A., Dutta, S., Nayak, D., Kaushik, S., Das, T., & Sa, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295257 · Cited by 333
“As a result, an adaptive immune response is generated with the invasion of anti-tumor M1 macrophages, CD8 + T cells, and natural killer (NK) cells, which maintains the in fl ammatory conditions to challenge cancer cells while also constantly replenishing their population (9, 10).”
BackgroundInfluentialTumor-Associated Macrophage Subsets: Shaping Polarization and Targeting
Zhang, Q., & Sioud, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087493 · Cited by 300
“For instance, TAMs can facilitate the recruitment of immunosuppressive cells such as Treg and Th2 cells by releasing chemokines including CCL2 and CCL20 [11,13,15,16].”
BackgroundAdvances in the role of STAT3 in macrophage polarization
Xia, T., Zhang, M., Lei, W., Yang, R., Fu, S., Fan, Z., Yang, Y., & Zhang, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160719 · Cited by 284
“However, in actuality, macrophage polarization is a dynamic process, and the distinction between M1 and M2 macrophages is a simplified explanation of the complex process of polarization, which involves the balancing of various cytokines and chemokines as well as the recruitment of other immune cells or cancer cells (5…”
BackgroundInfluentialBai, R., Li, Y., Jian, L., Yang, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 279
“Once entrapped, macrophages will gradually polarize into M2 subtypes and serve protumoral functions [22].”
BackgroundInfluentialMacrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO
Kashfi, K., Kannikal, J., & Nath, N. (2021) · Cells · doi:10.3390/cells10113194 · Cited by 225
“This cellular behavior diverges from their M2 analogs, which exist as anti-inflammatory cells that participate in immunosuppressive processes, tissue remodeling, and promoting tumor development in general [20,26].”
BackgroundThe role of tumor-associated macrophages in tumor immune evasion
Huang, R., Kang, T., & Chen, S. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05777-4 · Cited by 230
“On the other hand, M2 macrophages, often associated with TAMs, promote tumor growth through various mechanisms like immune suppression, angiogenesis, neovascularization, and stromal activation (Boutilier and Elsawa 2021).”
BackgroundFang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
“Whereas M1 macrophages have traditionally been viewed as anti-tumor cells, M2 macrophages participate in several pro-tumorigenic processes in cancer by regulating angiogenesis and lymphangiogenic activity, suppressing the immune system, inducing hypoxia, and promoting tumor cell proliferation and metastasis [121].”
BackgroundMacrophage polarization in inflammatory bowel disease
Zhang, K., Guo, J., Yan, W., & Xu, L. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01386-9 · Cited by 204
“Previous immunotherapeutic treatments for IBD have focused on reducing M1 macrophages and increasing M2 macrophages to reduce the damage caused by pro-inflammatory factors secreted by M1 macrophages in the intestine [113].”
BackgroundResistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“…can be identified as M1 or M2 macrophages in which M1 macrophages classically express pro-inflammatory cytokines and promote anti-tumor immunity whereas M2 macrophages function in favor of tumor progression through promoting angiogenesis, immunosuppression, hypoxia induction and metastasis [166].”
Regulatory Mechanism of M1/M2 Macrophage Polarization in the Development of Autoimmune Diseases
Peng, Y., Zhou, M., Yang, H., Qu, R., Qiu, Y., Hao, J., Bi, H., & Guo, D. (2023) · Mediators of Inflammation · doi:10.1155/2023/8821610 · Cited by 198
“M2 can be activated by IL4 and IL-13; can secrete anti-inflammatory cytokines including IL-10, IL-4, and transforming growth factor-β (TGF-β); can also produce vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF); can inhibit T cell proliferation and activation; and can participate in T…”
BackgroundMacrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials
Zhang, W., Wang, M., Ji, C., Liu, X., Gu, B., & Dong, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116930 · Cited by 178
Metabolic Reprogramming Induces Macrophage Polarization in the Tumor Microenvironment
Wang, S., Liu, G., Li, Y., & Pan, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.840029 · Cited by 181
Zheng, S., Wang, W., Shen, L., Yao, Y., Xia, W., & Ni, C. (2024) · Experimental Hematology & Oncology · doi:10.1186/s40164-024-00543-1 · Cited by 163
Advances in the study of macrophage polarization in inflammatory immune skin diseases
Xia, T., Fu, S., Yang, R., Yang, K., Lei, W., Yang, Y., Zhang, Q., Zhao, Y., Yu, J., Yu, L., et al. (2023) · Journal of Inflammation · doi:10.1186/s12950-023-00360-z · Cited by 164
Pericytes in the tumor microenvironment
Jiang, Z., Zhou, J., Li, L., Liao, S., He, J., Zhou, S., & Zhou, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216074 · Cited by 175
The role of RNA methylation in tumor immunity and its potential in immunotherapy
Li, Y., Jin, H., Li, Q., Shi, L., Mao, Y., & Zhao, L. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02041-8 · Cited by 184
“While M1 macrophages are generally considered anti-tumorigenic, and M2 macrophages are considered pro-tumorigenic [195, 202].”
BackgroundLi, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 158
Lactylation: novel epigenetic regulatory and therapeutic opportunities
Fan, H., Yang, F., Xiao, Z., Luo, H., Chen, H., Chen, Z., Liu, Q., & Xiao, Y. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00159.2022 · Cited by 168
Chang, J., Wu, H., Wu, J., Liu, M., Zhang, W., Hu, Y., Zhang, X., Xu, J., Li, L., Yu, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04033-6 · Cited by 167
“M2-polarized macrophages, commonly deemed tumorassociated macrophages (TAMs), were contributors to many pro-tumorigenic outcomes in cancer [57].”
BackgroundThe Role of Oxidative Stress in Tumorigenesis and Progression
Li, K., Deng, Z., Lei, C., Ding, X., Li, J., & Wang, C. (2024) · Cells · doi:10.3390/cells13050441 · Cited by 153
“In addition, the potential of converting M2-TAMs into the immune-promoting M1 subtype has been identified as a promising approach to combat clinically challenging carcinomas [84].”
BackgroundRen, Y., Wang, R., Weng, S., Xu, H., Zhang, Y., Chen, S., Liu, S., Ba, Y., Zhou, Z., Luo, P., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01831-w · Cited by 156
“M2 macrophages, in contrast, release inhibitory cytokines like IL-10 and TGF-β, which suppress immune responses and aid in tissue remodeling and inflammation eradication [129].”
BackgroundMolecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
Oršolić, N., & Jembrek, M. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810479 · Cited by 151
“Moreover, immunosuppressive mediators released by local inflammatory or tumor cells may attenuate the host antitumor response and promote tumor progression [258,262].”
Backgrounddos Santos, D. Z., de Souza, J. C., Pimenta, T. M., Martins, B. D. S., Ribeiro, R. S., Butzene, S. M. S., Tessarolo, N. G., Junior, P. C. M. L., Silva, I. V., & Rangel, L. B. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01178-1 · Cited by 149
“This can result in increased oxidative stress, as well as alterations in cell signaling pathways that can promote tumor growth and metastasis [72, 73], and including the secretion of cytokines in the tumor microenvironment [74, 75].”
BackgroundCancer-induced nerve injury promotes resistance to anti-PD-1 therapy
Baruch, E. N., Gleber‐Netto, F. O., Nagarajan, P., Rao, X., Akhter, S., Eichwald, T., Xie, T., Balood, M., Adewale, A., Na’ara, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09370-8 · Cited by 156
You, Y., Tian, Z., Du, Z., Wu, K., Xu, G., Dai, M., Wang, Y., & Xiao, M. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02222-z · Cited by 138
“Studies have shown that TAMs are able to induce EMT/CSCs through various signaling pathways such as the TLR4/IL10 pathways, the TGF-β/Smad2 pathway, the miR-30a/NF-κB/Snail signaling pathways, Wnt2b/ β-catenin/c-Myc signaling pathways, Stat3 pathways, and etc [3, 4, 25, 26].”
BackgroundThe CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
Hadiloo, K., Taremi, S., Heidari, M., & Esmaeilzadeh, A. (2023) · Biomarker Research · doi:10.1186/s40364-023-00537-x · Cited by 143
“However, the M1/M2 dichotomy is a simplified model, and these cells have an extreme spectrum of M1 to M2 phenotypes [21].”
BackgroundZhao, C., Song, W., Wang, J., Tang, X., & Jiang, Z. (2024) · Chemical Communications · doi:10.1039/d4cc06510g · Cited by 139
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 112
“In addition, M2 macrophages produce MMPs to regulate matrix remodelling, thus facilitating the invasion and metastasis of cancer [164].”
BackgroundTumor microenvironment and immunotherapy of oral cancer
Liu, C. X., Wang, M., Zhang, H., Li, C., Zhang, T., Liu, H. S., Zhu, S., & Chen, J. (2022) · European journal of medical research · doi:10.1186/s40001-022-00835-4 · Cited by 136
“Macrophages can transform their functions and phenotypes according to the surrounding environment [59].”
BackgroundPuttock, E. H., Tyler, E. J., Manni, M., Maniati, E., Butterworth, C., Ramos, M. B., Peerani, E., Hirani, P., Gauthier, V., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38093-5 · Cited by 136
“Of note, macrophages were associated with these signatures, and the majority of intra-tumoral macrophages are thought to exhibit an M2-like phenotype which correlates with poor prognosis in several malignancies, including ovarian cancer 22,23 .”
Huang, K., Han, Y., Chen, Y., Shen, H., Zeng, S., & Cai, C. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02205-6 · Cited by 145
Zhang, F., Lv, M., Wang, S., Li, M., Wang, Y., Hu, C., Hu, W., Wang, X., Wang, X., Liu, Z., et al. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.08.008 · Cited by 144
Wang, N.-H., Lei, Z., Yang, H.-N., Tang, Z., Yang, M., Wang, Y., Sui, J.-D., & Wu, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-6049 · Cited by 119
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
Huang, C. L., Li, J., Wu, R., Li, Y., & Zhang, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02344-4 · Cited by 127
Liu, J., Shi, Y., & Zhang, Y. (2023) · The EPMA Journal · doi:10.1007/s13167-023-00327-3 · Cited by 130
“In contrast, the low-risk group had a less infiltrated immune microenvironment characterized by the presence of macrophage M2 cells, CD4 + T cell memory resting cells, and mast resting cells, which lacked anti-cancer activity [94, 95].”
BackgroundImpaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 114
Dysregulation of immunity by cigarette smoking promotes inflammation and cancer: A review
Liu, Y., Lu, L., Yang, H., Wu, X., Luo, X., Shen, J., Xiao, Z., Zhao, Y., Du, F., Chen, Y., et al. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122730 · Cited by 116
Physiological Role of Bile Acids Modified by the Gut Microbiome
Kiriyama, Y., & Nochi, H. (2021) · Microorganisms · doi:10.3390/microorganisms10010068 · Cited by 112
Su, P., Jiang, L., Zhang, Y., Yu, T., Kang, W., Liu, Y., & Yu, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02717-5 · Cited by 110
“TAMs are heterogeneous cells and can be broadly classified into the classically activated phenotype (M1) and the alternatively activated phenotype (M2) depending on their distinct microenvironmental stimulating signals [10, 11].”
BackgroundAnti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
Babamohamadi, M., Mohammadi, N., Faryadi, E., Haddadi, M., Merati, A., Ghobadinezhad, F., Amirian, R., Izadi, Z., & Hadjati, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-023-06391-x · Cited by 107
Entezari, M., Taheriazam, A., Orouei, S., Fallah, S., Sanaei, A., Hejazi, E. S., Kakavand, A., Rezaei, S., Heidari, H., Behroozaghdam, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113609 · Cited by 105
Tumor-associated macrophage polarization in the inflammatory tumor microenvironment
Zou, Z., Lin, H., Li, M., & Lin, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103149 · Cited by 100
“MDSCs also express high levels of arginase-1, which promote macrophage polarization and contribute to immune suppression (8, 43, 44).”
BackgroundYang, Y., Liu, Q., Wang, M., Li, L., Yu, Y. M., Pan, M., Hu, D., Chu, B., Qu, Y., & Qian, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01859-4 · Cited by 110
“42 Previous studies have shown that the lactate-rich TME can educate recruited TAMs into M2-polarized TAMs.”
BackgroundMetabolism and polarization regulation of macrophages in the tumor microenvironment
Wang, J., Mi, S., Ding, M., Li, X., & Yuan, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215766 · Cited by 105
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 115
“180 During TKI treatment, tumor cells induce TAM M2 polarization.”
BackgroundCytokines: Can Cancer Get the Message?
Morris, R. M., Mortimer, T. O., & O'Neill, K. L. (2022) · Cancers · doi:10.3390/cancers14092178 · Cited by 108
“M1 macrophages can switch to become M2-type macrophages, or vice versa, depending on environmental conditions, such as inflammation, infection, hypoxia, injury, or cytokine secretion [8].”
BackgroundInfluentialThe Immune Regulatory Role of Adenosine in the Tumor Microenvironment
Xing, J., Zhang, J., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914928 · Cited by 277
“Macrophages in the TME can be polarized into opposite functional states, known as M1 and M2 polarization [71–73].”
BackgroundDistinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment
Hoekstra, M. E., Slagter, M., Urbanus, J. H. M., Toebes, M., Slingerland, N., de Rink, I., Kluin, R. J. C., Nieuwland, M., Kerkhoven, R. M., Wessels, L. F. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.010 · Cited by 102
“Conceivably, intratumoral IFN g sensing could result in reduced availability of bioactive TGF b , for instance through induction of a more pro-inflammatory macrophage state 39,40 (Figure 4H).”
BackgroundNovel tumor-associated macrophage populations and subpopulations by single cell RNA sequencing
Wang, J., Zhu, N., Su, L., Gao, Y., & Yang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264774 · Cited by 111
“C1Q + TAM subpopulation (43, 44, 50, 63) also expresses common genes with both M1 and M2 macrophages (5, 20, 147).”
BackgroundThe Role of Osteopontin in Tumor Progression Through Tumor-Associated Macrophages
Tan, Y., Zhao, L., Yang, Y., & Liu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.953283 · Cited by 104
“TAMs can constantly be subjected to transition between M1 and M2, and different phenotypes of macrophages can co-exist in TME (61, 62).”
BackgroundRen, L., Yi, J., Yang, Y., Li, W., Zheng, X., Liu, J., Li, S., Yang, H. S., Zhang, Y., Ge, B., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106376 · Cited by 98
Liu, D., Qin, H., Gao, Y., Sun, M., & Wang, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107258 · Cited by 105
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 100
Jin, X., Zhang, N., Yan, T., Wei, J., Hao, L., Sun, C., Zhao, H., & Jiang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1573039 · Cited by 99
“In contrast, alternatively activated M2 macrophages, stimulated by IL-4, IL-10, or IL-13, perform immunosuppressive and tissue-repair roles (53, 54).”
Emerging Roles of Macrophage Polarization in Osteoarthritis: Mechanisms and Therapeutic Strategies
Yuan, Z. L., Jiang, D., Yang, M., Tao, J., Hu, X., Yang, X., & Zeng, Y. (2024) · Orthopaedic Surgery · doi:10.1111/os.13993 · Cited by 99
STAT3 blockade ameliorates LPS-induced kidney injury through macrophage-driven inflammation
Lee, S. H., Kim, K. H., Lee, S. M., Park, S., Lee, S., Cha, R., Lee, J. W., Kim, D. K., Kim, Y. S., Ye, S., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01841-1 · Cited by 96
“These macrophages express surface receptors CD80, CD40, MHC-II, and CD86 and release proinflammatory cytokines, including TNF-α, IL-1β, IL-6, and iNOS, distinguishing them from M2-type macrophage surface markers (CD206, CD205, CD163, and Arg-1) [11–13].”
BackgroundYe, J., Zhang, J. C., Zhu, Y., Wang, L. Y., Jiang, X. L., Liu, B., & He, G. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.08.008 · Cited by 95
“Macrophages that infiltrate TME can be driven by tumor-derived secretions to acquire a polarized M2 phenotype, which is regarded as a pro-tumor macrophage phenotype 284 .”
BackgroundRecent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 94
“As described earlier, CAR-M has phagocytic activity against solid tumors—similar to M1 macrophages in the TME [121,122,125].”
BackgroundInfluentialTumor microenvironment: recent advances in understanding and its role in modulating cancer therapies
Shah, D. D., Chorawala, M. R., Raghani, N. R., Patel, R., Fareed, M., Kashid, V. A., & Prajapati, B. G. (2025) · Medical Oncology · doi:10.1007/s12032-025-02641-4 · Cited by 100
Sun, Q., Liu, Q., Zhou, X., Wang, X., Li, H., Zhang, W., Yuan, H., & Sun, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106419 · Cited by 93
Peng, Z., Tong, Z., Ren, Z., Ye, M., & Hu, K. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00665-y · Cited by 91
“2004; Boutilier and Elsawa 2021).”
BackgroundStrategies to Reverse Hypoxic Tumor Microenvironment for Enhanced Sonodynamic Therapy
Li, J., Yue, Z., Tang, M., Wang, W., Sun, Y., Sun, T., & Chen, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302028 · Cited by 78
Li, J., Wang, Y., Tang, M., Zhang, C., Fei, Y., Li, M., Li, M., Gui, S., & Guo, J. X. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02261-y · Cited by 95
“M1-type macrophages produce the cytokines IL-6 and TNF-α, which promote the inflammatory response [84, 85].”
BackgroundDias, A. M. M., Courteau, A., Bellaye, P., Kohli, É., Oudot, A., Doulain, P., Petitot, C., WALKER, P. M., Decréau, R. A., & Collin, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112388 · Cited by 82
Small molecule sonosensitizers in cancer therapy: recent advances and clinical prospects
Li, D., Zhu, Y., Yin, W., Lin, X., Kim, G., Liu, Z., Jung, S., Seo, J., Kim, S., Kim, J. S., et al. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00088b · Cited by 84
Zhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 111
“TAMs are abundant in TME, tumor blood vessels, and stromal regions, which have immunosuppressive effects and promote Tex (61).”
BackgroundCheng, Y., Zhong, X., Nie, X., Gu, H., Wu, X., Li, R., Wu, Y., Lv, K., Leung, G., Fu, C., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154757 · Cited by 84
Li, L., & Tian, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114504 · Cited by 79
Regulation of newly identified lysine lactylation in cancer
Gao, X., Pang, C., Fan, Z., Wang, Y., Duan, Y., & Zhan, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216680 · Cited by 84
Li, M., Sun, P., Tu, B., Deng, G., Li, D., & He, W. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00124.2024 · Cited by 76
Shao, S., Miao, H., & Ma, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1295684 · Cited by 70
“Such adaptability might enhance the tumor ’ s resilience against therapeutic strategies (31, 43 – 45).”
Li, D., Cao, D., Sun, Y., Cui, Y., Zhang, Y., Jiang, J., & Cao, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1331641 · Cited by 80
“M2 polarization is a common hallmark of TME, with downregulated IL-12 and upregulated IL-10, IL-4, and IL-13 as secretion pro fi les (94).”
BackgroundShou, Y., Wang, X., Chen, C., Liang, Y., Yang, C., Xiao, Q., Li, H., Wang, S., Shu, J., Tian, X., et al. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02570-6 · Cited by 69
“Hence, it is believed that they regulate adaptive Th2 immunity, promote angiogenesis and tissue repair, have anti-inflammatory effects, and are conducive to tumor growth [5].”
BackgroundAlmawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT
Xie, Y., Chen, Z., Zhong, Q., Zheng, Z., Chen, Y., Shangguan, W., Zhang, Y., Yang, J., Zhu, D., & Xie, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02381-1 · Cited by 65
“The tumor microenvironment (TME), which is composed of mesenchymal cells and immune cells that have been recruited, has immunosuppressive and tumorpromoting effects [5].”
BackgroundThe role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies
Wang, D., Ye, Q., Gu, H., & Chen, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984560 · Cited by 74
“M2 macrophages are regarded as the main components of TAMs, which exhibit a tumor-promoting effect and are dedicated to forming an immunosuppress ive microenvi ronment , whi le M1 macrophages show a tumor-inhibiting effect (84) (Figure 2).”
BackgroundAdvances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy
Yang, S., Wang, Y., Jia, J., Fang, Y., Yang, Y., Yuan, W., & Hu, J. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06616-7 · Cited by 74
“Both M1 and M2 TAMs are present throughout all phases of tumour progression, with M1 macrophages prevailing during the initial stage and M2 macrophages dominating during the intermediate and advanced stages [31].”
BackgroundYe, J., Lin, Y., Liao, Z., Gao, X., Lu, C., Lu, L., Huang, J., Huang, X., Huang, S., Yu, H., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00752-1 · Cited by 55
“2, Supplementary Table 2 and Supplementary Table 3. upregulated 49 – 52 , indicating that these cytotoxic XCL1 + CD8 + T cells were actually in a dysfunctional state with low clonal expansion and immuno-suppression.”
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Mortezaee, K., & Majidpoor, J. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00667-8 · Cited by 68
“Reduced expression of the M2 marker CD206 is related positively with a higher response in recurrent small cell carcinoma [32].”
BackgroundInfluentialCheruku, S., Rao, V., Pandey, R., Chamallamudi, M. R., Ravichandiran, V., & Kumar, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109569 · Cited by 67
Xiong, H., Zhai, Y., Meng, Y., Wu, Z., Qiu, A., Cai, Y., Wang, G., & Yang, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216732 · Cited by 68
Cellular crosstalk in fibrosis: Insights into macrophage and fibroblast dynamics
Froom, Z. S. C. S., Callaghan, N. I., & Huyer, L. D. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110203 · Cited by 70
“These macrophages exhibit pro-angiogenic functions and are commonly associated with tumor microenvironments (98 – 100).”
Chen, P., Wang, D., Xiao, T., Gu, W., Yang, H., Yang, M., & Wang, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110629 · Cited by 68
Bhattacharya, A., Alam, K., Roy, N. S., Kaur, K., Kaity, S., Ravichandiran, V., & Roy, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02926-4 · Cited by 66
“Previous studies have shown that M1 macrophages are anti-tumor, whereas tumor-associated macrophages (TAMs), also known as M2-polarized macrophages, are linked to pro-tumorigenic outcomes in cancer [225].”
Comorbidities in COPD: Current and Future Treatment Challenges
Mariniello, D. F., D’Agnano, V., Cennamo, D., Conte, S., Quarcio, G., Notizia, L., Pagliaro, R., Schiattarella, A., Salvi, R., Bianco, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030743 · Cited by 68
Tumor-associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products
Lafta, H. A., AbdulHussein, A. H., Al-Shalah, S. A. J., Alnassar, Y. S., Mohammed, N. M., Akram, S. M., Qasim, M. T., & Najafi, M. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230201145909 · Cited by 69
Astragaloside IV, as a potential anticancer agent
Xia, D., Li, W., Tang, C., & Jiang, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1065505 · Cited by 69
“They promote the growth, invasion, metastasis, and angiogenesis of cancer cells and are one of the main tumor-infiltrating immune cells (Boutilier and Elsawa, 2021).”
BackgroundRole of macrophages in pulmonary arterial hypertension
Zhang, M., Wang, C., Pang, X., Shi, J.-Z., Li, H., Xie, X., Wang, Z., Zhang, H., Zhou, Y., Chen, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152881 · Cited by 78
“Hypoxia stimulates alveolar macrophages to differentiate into M2 phenotype, which is required for vascular remodeling and subsequent establishment of PAH (111, 112).”
BackgroundWang, Z., Wang, S., Jia, Z., Hu, Y., Cao, D., Yang, M., Liu, L., Gao, L., Qiu, S., Yan, W., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2023.216184 · Cited by 66
Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)
Huang, J., Wu, Q., Geller, D. A., & Yan, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04716-0 · Cited by 66
“Conversely, tumors have the ability to induce the conversion of the M1-like phenotype to the M2-like phenotype, thereby shielding themselves from immune cell-mediated damage [61–63].”
BackgroundSalmonella as a Promising Curative Tool against Cancer
Aganja, R. P., Sivasankar, C., Senevirathne, A., & Lee, J. H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102100 · Cited by 62
Metadata
- Authors
- Boutilier, A. J., & Elsawa, S. F.
- Affiliations
- University of New Hampshire (US)
- Corresponding author
- Elsawa, Sherine F.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-29
- Volume
- 22
- Issue
- 13
- Pages
- 6995
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8268869
- OpenAlex
- W3173665490
- Cited by
- 1,631
- References
- 148
- Citations by year
- 2026: 281 · 2025: 409 · 2024: 429 · 2023: 359 · 2022: 144 · 2021: 9
- FWCI
- 24.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (P20 GM113131)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- macrophage polarization, tumor-associated macrophages, tumor microenvironment, tumor progression, angiogenesis, lymphangiogenesis, immunosuppression, hypoxia, metastasis, macrophage recruitment
- MeSH terms
- Tumor-Associated Macrophages, Animals, Hypoxia, Cell Transformation, Neoplastic, Humans, Inflammation, Macrophage Activation, Neoplasm Metastasis, Neoplasm Staging, Signal Transduction, Biomarkers, Immunophenotyping, Cytokines, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.